European equities traded in the US as American depositary receipts were flat late Wednesday morning, nudging 0.04% lower to 1,445.63 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical companies Genfit (GNFT) and Cellectis (CLLS), which rose 3.8% and 2.6% respectively. They were followed by brewing company Anheuser-Busch InBev (BUD) and telecommunications company VEON (VEON), which were up 1.8% and 1.6% respectively.
The decliners from continental Europe were led by pharmaceutical company Ascendis Pharma (ASND) and biopharmaceutical company Calliditas Therapeutics (CALT), which fell 12% and 2.6% respectively. They were followed by financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which lost 1.5%.
From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and software firm Endava (DAVA), which increased 3.6% and 3.4% respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and telecommunications operator Vodafone Group (VOD), which advanced 3.2% and 1.5% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and biotech firm Trinity Biotech (TRIB), which lost 8.1% and 4.4% respectively. They were followed by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Amarin (AMRN), which were down 2.5% and 1.8% respectively.
Comments